Article
CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Nov 2007
Setiawan Veronica Wendy, Schumacher Fredrick R, Haiman Christopher A, Stram Daniel O, Albanes Demetrius, Altshuler David, Berglund Göran, Buring Julie, Calle Eugenia E, Clavel-Chapelon Françoise, Cox David G, Gaziano J Michael, Hankinson Susan E, Hayes Richard B, Henderson Brian E, Hirschhorn Joel, Hoover Robert, Hunter David J, Kaaks Rudolf, Kolonel Laurence N, Kraft Peter, Ma Jing, Le Marchand Loïc, Linseisen Jakob, Lund Eiliv, Navarro Carmen, Overvad Kim, Palli Domenico, Peeters Petra H M, Pike Malcolm C, Riboli Elio, Stampfer Meir J, Thun Michael J, Travis Ruth, Trichopoulos Dimitrios, Yeager Meredith, Ziegler Regina G, Spencer Feigelson Heather, Chanock Stephen J
Abstract excerpt
CYP17 encodes cytochrome p450c17alpha, which mediates activities essential for the production of sex steroids. Common germ line variation in the CYP17 gene has been related to inconsistent results in breast and prostate cancer, with most studies focusing on the nonsynonymous single nucleotide polymorphism (SNP) T27C (rs743572). We comprehensively characterized variation in CYP17 by direct sequencing of exons...
Read the complete abstract on PubMed